

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
20 September 2007 (20.09.2007)

PCT

(10) International Publication Number
WO 2007/106525 A1

(51) International Patent Classification:

C07D 211/26 (2006.01) A61K 31/445 (2006.01)
 C07D 209/08 (2006.01) A61K 31/4523 (2006.01)
 C07D 211/58 (2006.01) A61P 9/14 (2006.01)
 C07D 211/96 (2006.01) A61P 11/00 (2006.01)
 C07D 213/40 (2006.01) A61P 19/02 (2006.01)
 C07D 401/06 (2006.01) C07D 487/18 (2006.01)
 C07C 275/26 (2006.01) C07D 295/20 (2006.01)
 C07C 275/28 (2006.01)

Richard, Jr. [US/US]; 3912 Trust Way, Hayward, California 94545 (US).

(21) International Application Number:

PCT/US2007/006412

(22) International Filing Date: 13 March 2007 (13.03.2007)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/782,172 13 March 2006 (13.03.2006) US

(71) Applicants (for all designated States except US): **THE REGENTS OF THE UNIVERSITY OF CALIFORNIA** [US/US]; 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200 (US). **ARÊTE THERAPEUTICS** [US/US]; 3912 Trust Way, Hayward, California 94545 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HAMMOCK, Bruce D.** [US/US]; 3134 Chesapeake Bay Avenue, Davis, California 95616 (US). **JONES, Paul D.** [US/US]; 120 Ravine Drive, Apt. 63B, Matawan, New Jersey 07747 (US). **MORISSEAU, Christophe** [FR/US]; 3376 Bonaire Road, West Sacramento, California 95691 (US). **HUANG, Huazhang** [CN/US]; 520 Alvarado Ave., Apt. 206, Davis, California 95616 (US). **TSAL, Hsing-Ju** [—/US]; 178 La Rue Road, #142, Davis, California 95616 (US). **GLESS,**

(74) Agents: **HOPKINS, Mark H.** et al.; Townsend and Townsend and Crew LLP, Two Embarcadero Center, 8th Floor, San Francisco, CA 94111 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:


— of inventorship (Rule 4.17(iv))

Published:

— with international search report
 — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PIPERIDINYL, INDOLYL, PIRINIDYL, MORPHOLINYL AND BENZIMIDAZOLYL UREA DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE FOR THE TREATMENT OF HYPERTENSION, INFLAMMATIONS AND OTHER DISEASES



(i) (57) Abstract: Compounds of the formula (I); wherein R^1 is a member selected from the group consisting of C_1 - C_8 alkyl, aryl- C_0 - C_8 alkyl, C_3 - C_{12} cycloalkyl and heterocyclyl, Y^1 is selected from the group consisting of a bond, $C(R^5)_2$, NR^5 and O; Y^2 is selected from the group consisting of a bond, NR^5 and O; each R^2 , R^3 and R^5 is independently selected from the group

consisting of H, alkyl and COR^6 ; A is heterocyclyl, optionally substituted with from 1 to 2 R^7 substituents; L is selected from the group consisting of a direct bond, C_1 - C_{12} alkylene, C_1 - C_{12} heteroalkylene, C_3 - C_6 cycloalkylene, arylene, heteroarylene, $-CO-$, $-SO_{in-}$ and $-Se-$; R^4 is selected from the group consisting of H, C_1 - C_8 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_8 heteroalkyl, aryl- C_0 - C_8 alkyl, C_3 - C_{12} cycloalkyl and heterocyclyl, are claimed. The compounds are inhibitors of the soluble epoxide hydrolase (sEH) and useful for the treatment of hypertension, inflammation, adult respiratory distress syndrome; diabetic complications; end stage renal disease; Raynaud syndrome and arthritis.